Patient characteristic | No. (%) |
---|---|
Median age (range) | 63 years (14–79 years) |
Sex | |
Male | 29 (74) |
Female | 10 (26) |
Current cancer | |
Metastatic melanoma | 24 (62) |
Cutaneous squamous cell carcinoma | 6 (15) |
Non-small cell lung cancer | 3 (8) |
Hepatocellular carcinoma | 4 (10) |
Duodenal adenocarcinoma | 1 (3) |
Malignant peripheral nerve sheath tumor-like melanoma | 1 (3) |
Checkpoint inhibitor | |
Ipilimumab | 14 (36) |
Anti-PD-1 agentsb | 30 (77) |
Nivolumab | 14 (36) |
Pembrolizumab | 17 (44) |
Combined use of ipilimumab and nivolumab | 1 (3) |
Prior solid organ transplantation | |
Renal | 23 (59) |
Hepatic | 11 (28) |
Cardiac | 5 (13) |
Allograft rejection before initiation of checkpoint inhibitor therapy (n = 24)c | 4 (17) |
Time between transplantation and initiation of checkpoint inhibitor therapy, median (range) | 9 years (0.92–32 years) |
Pre-emptive modification of the baseline immunosuppressive regimen at initiation of checkpoint inhibitor therapyd | 20 (51) |
Concomitant immunosuppressive therapy at initiation of checkpoint inhibitor therapye | |
Corticosteroid | 23 (59) |
mTOR inhibitor (sirolimus, everolimus) | 11 (28) |
Calcineurin inhibitor (tacrolimus, cyclosporine) | 19 (49) |
Other immunosuppressive therapies (azathioprine, mycophenolate mofetil) | 6 (15) |
No treatment | 1 (3) |